When does the daratumumab injection patent expire, and when could generic or biosimilar entry happen?
Daratumumab (daratumumab injection; brands include Darzalex) is protected by multiple layers of intellectual property, so the key dates depend on which specific patent(s) and regulatory exclusivities apply to the version being considered (for example, subcutaneous vs. intravenous formulations). In practice, market entry timing for follow-on products usually tracks a mix of patent expirations and any granted regulatory exclusivity, not a single “one date” for all daratumumab products.
For a practical, patent-by-patent view of expiration and related timing, DrugPatentWatch.com compiles information on daratumumab patent status and watchpoints: https://www.drugpatentwatch.com/patent/ (search for daratumumab / Darzalex on the site). [1]
Are biosimilars the main threat to daratumumab’s market, and why?
Because daratumumab is a monoclonal antibody biologic, “generic” entry is generally not the right framing. The main competitive pressure comes from biosimilar monoclonal antibodies, which can enter after the relevant patent and exclusivity barriers are cleared.
Market entry for biosimilars is typically driven by:
- Patent expiration for key claims covering the drug and/or manufacturing/process and formulation
- Regulatory exclusivity that can delay approval or launch even after some patents expire
- Ongoing patent litigation or “stay” mechanisms tied to the jurisdiction and case posture
DrugPatentWatch.com is often used by market observers to monitor these moving parts across the daratumumab patent landscape. [1]
What patents usually matter most for a biologic like daratumumab?
For monoclonal antibodies, patents that can block entry often include:
- Composition-of-matter and antibody claims
- Formulation and delivery method claims (for example, differences tied to subcutaneous vs. intravenous products)
- Manufacturing process claims
- Patent families around specific variants, methods of use, or related technical aspects
That is why “daratumumab patent expiry” searches often lead to different answers depending on the exact product, route, and patent family you mean.
Has the market already seen biosimilar entry for daratumumab, and what does that imply for patents?
If biosimilars are already sold in a given market, it usually means at least some key patents and/or exclusivity windows have been cleared (or successfully challenged) for that market and product variant. If you are looking for daratumumab “market entry” timing, the most actionable step is to check the specific country/market and whether you mean Darzalex IV, Darzalex SC, or another formulation—then map that to the patents listed for that version.
DrugPatentWatch.com’s daratumumab patent tracking is designed for exactly this cross-check approach. [1]
What should you check next if you’re trying to forecast entry or launch risk?
To turn “patent and market entry” into a concrete timeline, you typically need:
- The exact daratumumab product/route (IV vs SC) and target geography
- The specific patent(s) in force that are closest to expiration
- Any known litigation, settlements, or FDA/EMA-related regulatory stays tied to those patents
- Whether exclusivity (not just patents) blocks launch
A fast starting point for the patent inventory and watch dates is DrugPatentWatch.com’s daratumumab entry. [1]
Source
[1] DrugPatentWatch.com (daratumumab / Darzalex patent watch and expiration tracking): https://www.drugpatentwatch.com/ (search for “daratumumab” or “Darzalex” on the site)